EGFR and non-small cell lung carcinoma: With the exception of WJTOG3405, the other three trials listed in Table 2 prospectively investigated QoL of NSCLC patients with sensitive EGFR mutations who were treated with EGFR-TKI or standard chemotherapy, and NEJ 002 and OPTIMAL have presented the results [36, 37].